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ABSTRACT:
Mast cell neoplasms are characterized by abnormal growth and focal accumulation of 
mast cells (MC) in one or more organs. Although several cytokines, including stem cell 
factor (SCF) and interleukin-9 (IL-9) have been implicated in growth of normal MC, little 
is known about pro-oncogenic molecules and conditions triggering differentiation and 
growth of MC far enough to lead to the histopathological picture of  overt mastocytosis. 
The  anaplastic  lymphoma  kinase  (ALK)  has  recently  been  implicated  in  growth  of 
neoplastic cells in malignant lymphomas. Here, we describe that transplantation of 
NPM-ALK-transplanted mouse bone marrow progenitors into lethally irradiated IL-9 
transgenic mice not only results in lymphoma-formation, but also in the development 
of a neoplastic disease exhibiting histopathological features of systemic mastocytosis, 
including  multifocal  dense  MC-infiltrates,  occasionally  with  devastating  growth  in 
visceral  organs.  Transplantation  of  NPM-ALK-transduced  progenitors  into  normal 
mice or maintaintence of IL-9-transgenic mice without NPM-ALK each resulted in MC 
hyperplasia, but not in mastocytosis. Neoplastic MC in mice not only displayed IL-9, 
but also the IL-9 receptor, and the same was found to hold true for human neoplastic 
MC. Together, our data show that neoplastic MC express IL-9 rececptors, that IL-9 
and NPM-ALK upregulate MC-production in vivo, and that both'hits' act in concert to 
induce a mastocytosis-like disease in mice. These data may have pathogenetic and 
clinical implications and fit well with the observation that neoplastic MC in advanced 
SM strongly express NPM and multiple "lymphoid" antigens including CD25 and CD30.
Abbreviations used:
ALK - Anaplastic lymphoma kinase,     BM - Bone marrow,       CAE - Naphthol AS-D chloroacetate esterase,
FCS - Fetal calf serum,       IL - Interleukin,        IL-9 -Interleukin-9, 
MC - Mast cell(s),       NPM - Nucleophosmin,     rm -Recombinant mouse, 
SCF -Stem cell factor,       SM - Systemic mastocytosis,     Pc/pb - Plasmocytic/plasmoblastic
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INTRODUCTION
Systemic mastocytosis (SM) is a neoplastic disease of 
hematopoietic progenitor cells [1-6]. The clinical and his-
topathological picture of the disease is characterized by 
abnormal growth and accumulation of mast cells (MC) in 
one or more visceral organs, with or without organ damage 
[1-8]. However, little is known about the pathogenesis and 
evolution of SM, and molecular mechanisms underlying the 
growth of neoplastic MC in affected organs. In the human 
system, the KIT proto-oncogene as well as the KIT-ligand 
stem cell factor (SCF), have been implicated in abnormal 
growth of MC in MC hyperplasia and SM [9-20]. Like-
wise, SCF reportedly induces differentiation of human MC 
in vitro [9, 10]. In addition, overexpression of endogenous 
SCF or injection of recombinant SCF is associated with a 
local increase in MC in vivo, which can closely resemble 
a primary MC disease (mastocytosis) [11-13]. In patients 
with SM, several gain-of-function mutations in KIT have 
been detected and supposedly contribute to autonomous 
growth of MC in SM [14-20]. However, not all patients 
with SM exhibit KIT mutations [7, 8]. Moreover, in other 
species, the contribution of KIT and the KIT-ligand SCF to 
the development of SM is less well established.
In mice, several different cytokines promote the devel-
opment and differentiation of MC from their uncommitted 
bone marrow (BM) derived progenitors [21-28]. Among 
these cytokines are interleukin-3 (IL-3), IL-4, SCF, and 
IL-9 [21-28]. Especially SCF and IL-9 have been described 
to lead to MC hyperplasia when overexpressed or injected 
in mice [29, 30]. It has also been demonstrated that func-
tional  disruption  of  genes  encoding  IL-9,  SCF,  or  SCF 
receptor (KIT), is associated with MC-deficiency [29-33]. 
In  addition,  several  other  factors  and  the  microenviron-
ment have been implicated in the regulation of growth and 
survival of (normal) murine MC [34-40]. However, so far, 
little is known about conditions and pro-oncogenic ´hits´ 
required for full transformation of murine MC progenitors.
In previous studies, mutants of the KIT proto-oncogene 
have been described as regulators of growth of neoplas-
tic MC and thus as a potential trigger in SM in mice [41-
45]. However, apart from KIT, also other KIT-independent 
oncogenic molecules and triggers have been implicated in 
the development of mast cell tumors in mice [46-48]. Other 
studies have shown that ErbB can induce a mastocytosis-
like disease in mice, and can substitute for KIT as MC 
growth-promoting kinase in KIT-deficient animals [49, 50]. 
However, little is known so far about the potential role and 
relative contribution of all these oncogenes and cytokines 
in growth of neoplastic MC in SM.
The anaplastic lymphoma kinase (ALK) is a src-recep-
tor tyrosine kinase that is expressed in neoplastic B cells and 
T cells in several different lymphomas, but is not expressed 
in normal lymphohematopoietic cells [51-53]. In malignant 
lymphomas carrying the t(2;5)(p23;q35), ALK is usually 
fused to the nucleophosmin (NPM) gene [54-56]. We and 
others have shown that NPM-ALK leads to the formation 
of malignant lymphomas in mice [57-60]. In addition, it 
was  found  that  transplantation  of  NPM-ALK-transduced 
BM cells into IL-9 transgenic mice results in the genera-
tion of various lymphoid and plasmacytoid tumors [61]. So 
far, however, the ALK tyrosine kinase and NPM have not 
been analyzed in the context of mastocytosis.
In this article, we show that the MC-targeting cytokine 
IL-9 and the lymphoma-related oncoprotein NPM-ALK act 
in concert to promote the growth of MC. In fact, whereas 
either ´hit´ alone was found to lead to an increase in tissue 
MC in visceral organs in mice without fulfilling histopatho-
logical criteria of SM, transplantation of NPM-ALK-trans-
fected progenitors into lethally irradiated IL-9 transgenic 
mice was found to be associated not only with lymphoma-
formation, but also with the development of a neoplasm 
resembling systemic mastocytosis, sometimes with aggres-
sive destructive growth indicative of advanced SM.
MATERIALS AND METHODS
Animals
FVB/N mice [62] were used as wild-type control and 
were purchased at 4–6 weeks of age from Jackson Labora-
tories (Bar Habor, ME). IL-9 transgenic mice were gener-
ated by microinjecting the IL-9 transgene-construct into the 
pronuclei of fertilized eggs of FVB mice as described [60, 
63]. The homozygous transgenic mouse strain used in this 
study was designated Tg54. This strain maintained serum 
IL-9 levels of >1 µg/ml, while IL-9 was undetectable in 
serum of control FVB/N mice. Transgenic mice were gener-
ated at the Ludwig Institute for Cancer Research (Brussels, 
Belgium) and were bred and analyzed at the University of 
Schleswig-Holstein, Campus Lübeck (Lübeck, Germany). 
All animal work was performed according to local guide-
lines and international guidelines for animal care and pro-
tection. Animals were transplanted at 8–12 weeks of age.
NPM–ALK retrovirus
A  retroviral  vector  containing  the  NPM-ALK  onco-
gene derived from a human NPM-ALK-positive anaplastic 
large cell lymphoma was cloned into the retroviral vector 
pLXSN to generate pL-NPM-ALK-SN [61]. In this vector, 
the 5’ viral LTR promoter/enhancer elements control the 
expression of the NPM-ALK gene. The SV40 early pro-
moter (PSV40e) regulates the expression of the neomycin 
resistance gene (NeoR), which allows antibiotic selection in 
eukaryotic cells. Helper virus-free stocks of a vector con-
trol virus (mock virus) and the NPM-ALK-retrovirus were 
obtained from cloned ecotropic packaging cells GT+E86. 
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infected with the virus, expressed the NPM–ALK protein 
as  determined  by  RT-PCR  and  immunohistochemistry 
using an anti-ALK-1 antibody. Cells for retroviral infec-
tion were harvested from the marrow of the long bones 
of young TG54 and FVB/N mice and were cultured with 
infective supernatants [61].
Transduction of BM cells and transplantation into 
irradiated recipients
BM cells were harvested from femurs of 8 to 12-week-
old male IL-9 transgenic mice or FVB/N control mice, 6 
days after these mice had been treated with 150 mg/kg 
5-fluorouracil (Roche, Basel, Switzerland). Cells (5 x 105 
cells/ml) were cultured for 24 hours in DMEM (Invitrogen, 
Karlsruhe,  Germany)  supplemented  with  10%  fetal  calf 
serum (FCS) (Invitrogen), recombinant mouse (rm) SCF 
(100 ng/ml), rmIL-6 (10 ng/ml), and rmIL-3 (10 ng/ml) (all 
from  R&D  Systems, Wiesbaden,  Germany).  Donor  BM 
cells were transduced with L-NPM–ALK-SN virus super-
natant with a multiplicity of infection (m.o.i.) of >5 at 37°C 
for 24 hours in DMEM with 10% FCS, rmSCF, rmIL-6, 
rmIL-3 and 5 mg/ml polybrene (Sigma Chemical Co., St 
Louis, MO, USA). After infection, BM cells were selected 
for 48 hours in medium complemented with G418R (BD 
Biosciences  Clontech,  Heidelberg,  Germany)  and  there-
after used for transplantation into lethally irradiated mice. 
One million cells were injected into one of the lateral tail 
veins of female recipient mice (8 to 10-week-old) after they 
had received a lethal dose of total body irradiation (5 Gy 
twice within a 3 hour-interval; 1.75 Gy/min; X-ray). There-
after, mice received acidic water (pH 2.8) and sterile food, 
and were observed for the development of tumors. Three 
different experimental groups of mice were analyzed. In 
group ´1´, a total of sixty two female IL-9 transgenic mice 
(TG54) were used and transplanted with L-NPM–ALK-
SN-transduced  BM  cells  from  10-week-old  male  IL-9 
transgenic donors, resulting in fifty one IL-9/NPM-ALK 
double positive mice (11 mice died during the first 10 days 
after transplantation). Group ´2´ contained a total of six-
teen female IL-9 transgenic mice (TG54) and served as 
control group. These animals received LXSN-only infected 
BM cells, resulting in IL-9/control mice. In group ´3´, a 
total of seventeen female wild-type mice (FVB/N) were 
transplanted with L-NPM-ALK-SN-transduced BM from 
10-week-old  male  wild-type  donors,  resulting  in  NPM–
ALK  mice.  A  summary  of  animal  groups  examined  is 
shown in Table 1. Ten female wild-type mice were trans-
planted with LXSN-only for control (negative for both IL-9 
and NPM-ALK). In select experiments, 2 x 105 lymphoma 
cells from tumor-bearing mice were obtained and injected 
intraperitoneally into syngeneic mice. Tumors developing 
in these secondary recipients were analyzed in the same 
way as primary tumors.
Necropsy and histopathological examination of tissues 
sections
A complete necropsy was performed in each mouse. 
Moribund  mice  were  euthanized  and  examined  for  evi-
dence  of  tumor-formation.  Thymus,  lymph  nodes,  BM, 
spleen, stomach, gut, peyer´s pathches and solid organs 
were analyzed by routine histology. Specimens were fixed 
by 4% paraformaldehyde (24 hours) before being embed-
ded in paraffin. Tissue sections (3–5 µm thick) were placed 
on glass slides, dehydrated, dewaxed, and then stained with 
haematoxylin-eosin  (H+E)  or  Giemsa  solution.  In  addi-
tion, tissues sections were examined by toluidine blue- and 
Berberine  sulphate  staining.  For  toluidine  blue  staining, 
deparaffinized sections were stained in 1% toluidine blue 
(Merck; Darmstadt, Germany) dissolved in methanol (2-5 
minutes), washed, and mounted after air-drying. For Ber-
berine sulphate staining, deparaffinized sections were fixed 
in ethanol/acetic acid (3:1) for 15 minutes, washed in etha-
nol (15 minutes) and water (10 minutes), and then exposed 
to 0.02% berberine sulphate (Serva, Heidelberg, Germany) 
dissolved in water (pH 4 with 1% citric acid). Slides were 
then washed in water (pH 4.0 with 1% citric acid) for 5 
Mouse Species and 
Treatment
Lymphoblastic 
Lymphoma T-Cell 
Type
Plasmocytoma/ 
Plasmoblastic 
Lymphoma
Mast cell 
Hyperplasia 
only1 
Systemic 
Mastocytosis, 
small lesions
Systemic 
Mastocytosis, 
large lesions
Mast cell 
sarcoma or 
myeloid sarcoma
wt 0/2 0/2 0/2 0/2 0/2 0/2
IL-9+mock 4/16 0/16 12/16 0/16 0/16 0/16
wt+NPM/ALK 0/17 7/17 10/17 0/17 0/17 0/17
IL-9+NPM-ALK 17/51 33/51 10/51 10/512 16/512 4[1+3]/513
Table 1.  Histologic patterns and neoplasms developing in wild type wt- and IL-9 transgenic mice transplanted with 
NPM-ALK-infected marrow or with mock infected control marrow
The number of diseased animals is compared with the total number of animals included in each series of experiments. The majority 
of animals diagnosed to have mastocytosis also suffered from one or more malignant lymphomas. 1 In these mice, only mast cell 
hyperplasia but no mastocytosis-like disease developed. 2 Some of these mice developed both small lesions and larger lesions. One 
mouse developed a mast cell sacoma and presented with additonal SM lesions. In the “double hit” group, not all mice developed 
systemic mast cell disease – in fact, a mast cell disease was difficult to recognize when lymphomas developed very rapidly. 3 Of 
these 4 animals, 1 developed mast cell sarcoma/leukemia, and 3 a myelosarcoma (myelomonocytic sarcoma).107      Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
minutes, air-dried, and mounted. Larger tumor lesions were 
dispersed and subjected to flow cytometry, or were snap 
frozen in liquid nitrogen for immunohistochemical analy-
sis.
Immunohistochemistry in mouse tissues
Affected  mouse  tissues  were  characterized  immuno-
phenotypically using the ABC-technique [59]. A panel of 
biotinylated first-step antibodies (all purchased from BD 
Bioscience, Heidelberg, Germany) was used: B-cell mark-
ers included CD45R, CD19, CD38 and CD23, and T-cell 
markers included CD5, CD25, CD4, CD8 and CD3e. For 
detection of these antigens, an alkaline phosphatase-con-
jugated streptavidin complex (Dako, Hamburg, Germany: 
K5005) was applied. For staining with mouse anti-human 
ALK-1 antibody M7185 (Dako) (heat retrieval at pH 9,5; 
work dilution: 1:25), anti-tryptase antibody M7196 (Dako) 
(heat retrieval at pH 9.5; dilution: 1:1,250), and anti-human 
KIT  antibody  (Labvision/Medac,  Hamburg,  Germany: 
K3954, applied according to the manufacturer´s instruc-
tion), the Dako-ARK kit (animal research kit) was applied. 
The  polyclonal  antibodies  anti-lambda,  anti-kappa,  anti-
IgA,  anti-IgG  and  anti-IgM,  and  secondary  biotinylated 
goat anti-rabbit antibodies (all from Dako) were detected 
with goat anti-rabbit antiserum (Labvision/ Medac; ultravi-
sion polymer, ready to use) according to the manufacturer´s 
instructions. Microscopic evaluation and fotographic acqui-
sitions were performed by using a MC200 chip microscope 
camera on a Zeiss Axioskop 2 plus  microscope (Carl Zeiss 
GmbH,  Jena,  Germany)  equipped  with  Planapochromat 
objectives (2.5x, 10x, 20x, 40x, 63x, 100x) and a numeric 
aperture of 1.4 using oil (Carl Zeiss GmbH). Images were 
obtained by using Adobe Photoshop CS2 software supply 
(Adobe, San Jose, CA) and processed with Power Point 
software, release 2003 (Microsoft, Redmont, WA). 
Evaluation of NPM-ALK mRNA expression by reverse 
transcription of RNA and quantitative PCR (qPCR)
Total RNA was extracted from 5 to 8 sections (25 µm 
thick) obtained from freshly frozen tissue blocks of mouse 
organs  using  Trizol  reagent  (Life  Technologies  GmbH, 
Karlsruhe, Germany). Total RNA was converted into cDNA 
using Superscript reverse transcriptase according to the man-
ufacturer’s  recommendations  (Life Technologies  GmbH, 
Karlsruhe, Germany). Expression of mRNA specific for 
the human NPM-ALK fusion gene (accession no. U04946) 
was analyzed using cDNA populations derived from sev-
eral  organs  and  tumors  of  two  transgenic  mice  (M780, 
M781) and one wild-type mouse (FVBN). The following 
primers  were  used:  NAF  (NPM-ALK-Forward  Primer): 
AGCACTTAGTAGTGTACCGCCGGAAGCACC (break-
point spanning) and NAR (NPM-ALK-Reverse Primer): 
TTCCATGAGGAAATCCAGTTCGTCC.  The  amplified 
product was 341 bp in size. NPM-ALK expression was 
compared to expression of the housekeeping gene mPBGD 
(accession no. NM_013551). The following primers were 
used to amplify a 428 bp mPBGD fragment: mPBGDF2: 
CAGACCGACACTGTGGTGGC  (exon  spanning)  and 
mPBGDR2: CTTCCGAAGGCGGGTGTTGAG. Standard 
curves for NPM-ALK and mPBGD were generated from 
serial dilutions of cDNA (100-104). According to the equa-
tion E=10-1/slope the efficiency of amplification was calcu-
lated to be E=1.8 for NPM-ALK and E=1.95 for mPBGD. 
PCR reactions were prepared using the ‘LightCycler Fast-
Start DNA MasterPLUS SYBR Green I kit’ and according 
to the instructions of the manufacturer. All samples were 
analysed in duplicates. PCR reactions were performed as 
follows: denaturing: 95°C; amplification (45 cycles): 95°C 
for 10 seconds, 55°C for 10 seconds, and 72°C for 25 sec-
onds; melting: 65°C for 15 seconds; cooling: 40°C for 30 
seconds. For quantification of NPM-ALK mRNA in tumor 
tissues, real time PCR was performed as described previ-
ously [64].
Evaluation of IL-9 and IL-9 receptor (IL-9R) mRNA 
expression by reverse transcription of RNA and qPCR
For  detection  and  quantification  of  IL-9  mRNA  and 
IL-9  receptor  mRNA  in  mouse  tissues  and  human  neo-
plastic mast cells (HMC-1), standard PCR protocols were 
applied. Prior to RNA isolation and qPCR, HMC-1 cells 
were incubated with 1 µg polysaccaride (LPS, Sigma) in 
10 ml medium for 4 hours. The qPCR was carried out using 
the LightCycler FastStart DNA Master Plus SYBR Green I 
Table 2.  PCR Primers 
Primer pairs were designed according to published sequences for mouse and human genes.
Primers - Mouse Forward primer (For) Reverse primer (Rev)
mIL9 (NM_008373) For: 5´-tgattgtaccacaccgtgct-3 Rev: 5´-gcttttctgcctttgcatct-3´
mIL9R (NM_008374) For: 5´-atgggacaggaacaggtcag-3´ Rev: 5´-aggtcactccaacgatacgg-3´
beta-mActin (NM_001101) For: 5´-tgacgaggcccagagcaagagag-3´ Rev: 5´ctaggagccagagcagtaatctg-3´
Primers - Human
hIL9 (NM_000590) For: 5´-tctgacaactgcaccagacc-3´ Rev: 5´-ttgcctctcatccctctcat-3´
hIL9R1 (NM_002186) For: 5´-agctatgagctggccttcaa-5´ Rev: 5´-ccacatcatcctccagtgtg
hIL9R2 (NM_176786) For: 5´-agctatgagctggccttcaa-3´ Rev: 5´-ccacatcatcctccagtgtg-3´108               Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
Kit, according to the manufacturer´s instructions (Roche). 
For each single reaction, 3 µl of cDNA was used. The reac-
tion was initiated with a 10 minute-denaturation step at 
95°C, and terminated with a 30 second cool-step at 40°C. 
The cycling protocol consisted of a denaturation step at 
95°C for 10 seconds, annealing at 56°C (10 seconds), and 
extension step at 72°C for 25 seconds, and was repeated 
45 times. Ramp time for all steps was 20°C/second. Rela-
tive  quantification  was  performed  by  the  2-delta-delta-
C(T) method employing β-actin as a housekeeping gene as 
described [65]. For PCR the Pure Taq Ready-To-Go PCR 
beads  system  of  GE  Healthcare  (Cat.  No.  27-9559-01) 
was used. Beads were supplemented with 10 pmol of each 
primer, DNA and HPLC grade H2O to a final volume of 25 
µl. Each PCR cycle consisted of 30 seconds denaturation 
at 94°C, 30 seconds annealing at 56 °C, and 90 seconds 
elongation at 72°C, and was repeated 30 times. Initial dena-
turation was performed for two minutes at 94°C, and final 
elongation for seven minutes at 72°C. Electrophoresis was 
performed on a 2% agarose gel. Primers used in qRT- and 
PCR experiments are shown in Table 2.
Culture of HMC-1 cells and stimulation experiments
The human mast cell line HMC-1, established from neo-
plastic MC of a patient with MC leukemia [66] was kindly 
provided  by  Dr.  J.H.  Butterfield  (Mayo  Clinic,  Roches-
ter, MN). HMC-1 cells were grown in Iscove´s modified 
Dulbecco´s medium (IMDM) (Gibco Life Technologies, 
Gaithersburg, MD) with 10% FCS (PAA laboratories, Pas-
ching, Austria), L-glutamine, and antibiotics at 37°C and 
5% CO2. Two subclones of HMC-1 were used, namely 
HMC-1.1 harbouring the KIT mutation V560G but not KIT 
D816V, and a second subclone, HMC-1.2, harbouring KIT 
V560G and D816V. HMC-1 cells were re-thawed from an 
original stock every 4-8 weeks and were passaged weekly. 
As  control  of  ´phenotypic  stability´,  HMC-1  cells  were 
periodically checked for expression of surface KIT and the 
down-modulating effect of IL-4 (100 U/ml, 48 hours) on 
KIT-expression. In stimulation experiments, HMC-1 cells 
were cultured in the absence or presence of LPS (0.1 µg/
ml) for 4-24 hours (37°C), or in the absence or presence 
of recombinant human IL-9 (5-100 ng/ml) (R&D systems, 
Wiesbaden, Germany) for 72 hours (37°C). After exposure 
to IL-9, uptake of 3H-thymidine was determined. All exper-
iments were performed in triplicates.
Flow cytometry
Direct immunofluorescence staining of dispersed mouse 
tissue cells was performed using phycoerythrin (PE)-con-
jugated  rat  monoclonal  antibodies  (mAb)  against  B-cell 
antigens (CD45R, CD19, CD38 and CD23), T-cell antigens 
(CD5, CD25, CD4, CD8 and CD3e), and myeloid antigens 
(CD11c, CD34) (all from BD Bioscience). HMC-1 cells 
were  analyzed  by  flow  cytometry  using  PE-conjugated 
mAb 104D2 (IgG1) directed against KIT (Becton Dickin-
son), mAb 33423 (IgG1) directed against the human IL-9 
receptor  (R&D  systems),  and  an  isotype-matched  IgG1 
control  antibody.  The  anti-IL-9  receptor  antibody  was 
detected by a second step FITC-labeled goat anti-mouse 
IgG antibody (R&D systems). Mouse cells and HMC-1 
cells (each 10,000 per test) were analyzed on a FACScan 
(BD Bioscience). All staining reactions were controlled by 
isotype-matched antibodies.
Examination of primary neoplastic MC for expression 
of NPM, ALK, IL-9 and IL-9 receptor by immunohis-
tochemistry
In 19 patients (age 26-63 years) with SM, immunohis-
tochemistry was performed on sections obtained from for-
malin-fixed and paraffin-embedded BM samples. Informed 
consent was obtained in each case before BM biopsy. Of 
the  19  patients,  7  suffered  from  indolent  SM  (ISM),  2 
from  smouldering  SM  (SSM),  4  from  SM-AHNMD,  3 
from aggressive SM (ASM), and 3 from mast cell leuke-
mia (MCL). Expression of tryptase, CD25, CD30, NPM, 
and ALK were analyzed in BM sections by indirect immu-
nohistochemistry using a published protocol [67] and the 
following antibodies: anti-tryptase mAb G3 (Santa Cruz 
Biotechnology, Santa Cruz, CA, 1:500), anti-CD25 mAb 
4C9 (Novocastra, Newcastle upon Tyne, UK), anti-CD30 
mAb Ber-H2 (Dako, Glostrup, Denmark; 1:20), mAb 376 
against nucleophosmin (Dako; 1:800), and anti-ALK mAb 
ALK1  (Dako;  1:25).  3,3-diaminobenzidine  (DAB)  was 
used as chromogen. Slides were counterstained in Mayer´s 
Hemalaun. For detection of IL-9 and IL-9R, a three step 
biotin-free  polymer  detection  method  was  used  after 
heat-induced epitope retrieval, according to the protocol 
provided by the manufacturer (UltraVision LP Detection 
System HRP Polymer & DAB Plus Chromogen, Labvison, 
Thermo-Fisher, provided by Medac, Hamburg Germany). 
The dilutions of the antibodies used were 1:200 for rabbit 
anti-IL-9 (R&D Systems), and 1:400 for mouse anti-IL-
9R mAb (R&D Systems). Horseradish peroxidase and 3,3’ 
diaminobenzidine/H2O2  were  applied  yielding  a  brown 
color reaction. Hematoxylin was used as counter-stain. The 
photomicrographs were obtained using a Zeiss Axiophot 
microscope (Carl Zeiss, Jena, Germany).
RESULTS
Retroviral transfer of NPM-ALK into primary mouse 
BM cells and detection of NPM-ALK mRNA in 
infected cells after transplantation
In four independent experiments, 51 IL-9 transgenic 
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mice with Neo+ (wt) BM cells were analysed. NPM-ALK+ 
BM cells were transplanted into 17 FVB/N wild-type mice 
(not  transgenic  for  IL-9),  which  served  as  control.  As 
assessed by real-time PCR [64, 65], NPM-ALK mRNA 
was found to be expressed in all tumors in IL-9 transgenic 
mice  transplanted  with  pL-NPM-ALK-SN-transfected 
cells (Figure 1A), but not in IL-9 transgenic mice trans-
planted  with  Neo+(wt)-transfected  cells  (Figure  1B).  In 
mice  transplanted  with  pL-NPM-ALK-SN-transfected 
cells, the levels of NPM-ALK mRNA varied slightly from 
tissue to tissue and from tumor to tumor. Nevertheless, sig-
nificant levels of NPM-ALK mRNA were detectable in all 
tissues (organs) affected with mastocytosis regardless of 
the presence or absence of a lymphoma, and without differ-
ences in NPM/ALK mRNA levels among animals exam-
ined (Figure 1A).
Both NPM-ALK and IL-9 induce mast cell hyperplasia 
in mice
As assessed by immunohistochemistry of BM sections 
and tissue sections in other organs, a slight to moderate 
increase in mast cells was found in IL-9 transgenic mice as 
well as in FVB/N (IL-9-negative) mice transplanted with 
pL-NPM-ALK-SN-transfected  cells,  but  not  in  FVB/N 
control mice transplanted with pLXSN-transduced (neo+) 
BM cells (Table 1). These data suggest that both IL-9 as 
well as NPM-ALK promote growth and/or differentiation 
of MC (progenitors) in vivo. Regarding IL-9, these data are 
consistent with the notion that IL-9 is an MC growth factor 
in mice [27]. However, under the experimental conditions 
applied, neither IL-9 nor NPM-ALK alone (as single “hit”) 
were found to lead to the histopathological picture of mas-
tocytosis  (focal  MC  accumulations  resembling  SM)  in 
any animal and organ examined (BM, spleen, liver, lung, 
thymus, gastrointestinal tract) (Table 1).
NPM-ALK and IL-9 cooperate in producing a masto-
cytosis-like disease in mice
All  IL-9-transgenic  mice  that  had  received  NPM–
ALK-transduced hematopoietic precursor cells developed 
hematopoietic malignancies, including various types of lym-
phomas (Tables 1 and 3). Tumor development was detected 
within 30 weeks. Macroscopically, most mice developed 
prominent abdominal lymph node masses, including peri-
pancreatic lymph nodes, retroperitoneal lymph nodes, and 
splenomegaly. Most of these tumor lesions were found to 
contain lymphoma cell infiltrates, confirming previous data 
[61]. In 4 cases, immature myeloid neoplasms (resembling 
myelosarcoma  or  MC  sarcoma/leukemia)  were  detected 
(Tables 1 and 3). Most significantly, however, we found 
that apart from lymphomas, substantial accumulations of 
MC in various organs developed in a significant number 
of (27/51) animals (Tables 1 and 3). In a subgroup of these 
animals (n=15), larger lesions of MC with typical clusters 
or even sheets of MC were found. IL-9/NPM-ALK+ mice 
with no apparent accumulations of MC (n=15) died early, 
some during the acute period after transplantation (marrow 
aplasia),  others  from  aggressive  lymphomas,  suggesting 
that  MC  neoplasms  developed  later  than  lymphomas  in 
mice. Infiltrates of neoplastic MC were found in various 
organs and tissues including the BM (Figure 2), the spleen 
(Figure 3), liver (Figure 4), lymph nodes, thymus, gastro-
intestinal tract (stomach and gut) (Figure 4), lung (Figure 
4), and kidney. In most animals, MC accumulations were 
found to resemble an MC neoplasm (mastocytosis) with 
dense  focal  MC  aggregates  (Figure  2-4).  MC  infiltrates 
Figure 1. Expression of NPM-ALK mRNA, IL-9 mRNA, and IL-9 
receptor mRNA in mouse tissues. (A) After retroviral overexpres-
sion of NPM-ALK in IL-9 transgenic mice, an increase in mast cells 
in various organs was found, which is indicated by the following 
score (bottom line on x axis):  +, elevated levels of mast cells; ++, 
markedly elevated levels of mast cells; +++, highly elevated levels 
of mast cells. In the same organs, expression of NPM-ALK mRNA 
(open bars) as well as IL-9 mRNA (hatched bars) was demonstra-
ble by qPCR. A series of 18 animals is shown. The following organs 
were analyzed in these animals: thymus (1), liver (2), spleen (3), 
lung (4), gut (5), kidney (6), gut (7), spleen (8), spleen (9), liver 
(10),  kidney  (11),  gut  (12),  stomach  (13),  spleen  (14),  stomach 
(15), stomach (16), stomach (17), and thymus (18). qPCR was per-
formed as described in the text. Interestingly, we were also able 
to demonstrate expression of significant amounts of IL-9 recep-
tor (IL-9R) mRNA (black bars), probably expressed in mast cells, 
in all tissues and organs examined. B: Expression of NPM-ALK 
mRNA levels, IL-9 mRNA levels, and IL-9 receptor (IL-9R) mRNA 
levels in various organs in an IL-9 transgenic mouse transplanted 
with Neo+(wt)-transfected cells. As visible, IL-9 transcripts were 
detected  in  all  organs,  whereas  NPM-ALK  mRNA  was  virtually 
undetectable. Interestingly, in IL-9 transgenic mice (without NPM-
ALK expression), we also were unable to detect substantial levels 
of IL-9 receptor mRNA by qPCR. In control mice, neither IL-9 nor 
IL-9 receptor mRNA or NPM-ALK mRNA was detected (not shown).
 +     = elevated levels of mast cells
 ++   = markedly elevated levels of mast cells
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were found either as an isolated lesion (without lymphoma) 
or together with a co-existing lymphoma-lesion at the same 
tissue site.
Histology of mast cell infiltrates in IL-9 transgenic 
NPM-ALK+ mice
MC accumulations could easily be detected by Giemsa-
staining in tissue sections in IL-9 transgenic NPM-ALK+ 
animals (Figure 2-4). In a few animals, some of the lesions 
showed a more diffuse infiltration pattern resembling MC 
hyperplasia  rather  than  true  mastocytosis  (Table  1).  In 
a majority of the animals with advanced MC infiltration, 
however, most lesions showed dense compact clusters of 
rather mature and moderately or even well granulated MC 
(Figures 2-4). In most of these animals, the lesions did not 
show histological signs of aggressive disease or a devastat-
ing growth pattern (Figures 2-4). In a few animals, how-
ever, MC aggregates extended to more confluent sheets of 
MC with associated organ fibrosis or even signs of destruc-
tive growth, consistent with the diagnosis of an aggressive 
MC disease (n=15/51) or even mast cell sarcoma (n=1/51). 
A summary of MC disorders detected in mice is shown 
in Tables 1 and 3. In general, MC lesions were found in 
most visceral organs in IL-9 transgenic NPM-ALK+ mice. 
In several animals, MC aggregates were also found in the 
lungs (Figure 4A). Occasionally, the kidneys or the thymus 
were found to be infiltrated by neoplastic MC. In one case, 
the thymus was destroyed by a large MC infiltrate exhibit-
ing a sarcoma-like growth pattern. A summary of involved 
organs  in  affected  IL-9  transgenic  NPM-ALK+  mice  is 
shown in Table 3. 
Table 3.  Organs involvement with mast cell disease/accumulation in IL-9-transgenic NPM-ALK+ mice
Experiment MC-accumulation 
x/n mice
Organ involvement by substantial mast cell 
accumulations 
Main histologic diagnosis             
#1 1/10  spleen, stomach   SM + pc
#2  6/10 BM, LN, spleen, kidney, lung, stomach, gut  SM + pbl
LN, spleen, kidney, lung, stomach, gut    SM + pc
kidney, heart, lung SM + pc  
liver, lung, stomach, thymus  SM + pc + mastsrc
BM, LN, spleen, liver, lung, stomach, gut  SM + pc + mysarc
LN, spleen, lung, stomach, gut SM + pc
#3    6/14  spleen  SM + pc
spleen, liver, lung, stomach SM + pc
spleen, stomach, gut  SM + pc
LN, spleen, stomach  SM + pc
BM, spleen, lung, stomach, gut  SM + pc + T-lb
BM, LN, spleen, lung, stomach, gut SM + pc
#4    14/17  spleen, liver, lung, stomach, thymus, gut  SM + pc + pbl + T-lb
BM, spleen, liver, lung  SM + pc
LN, spleen, liver, kidney, lung, stomach, gut  SM + pc
spleen, liver, gut  SM + pc + T-lb
BM, spleen, liver, lung    SM + pbl
LN, lung, stomach  SM + T-lb
liver, heart, lung, gut  SM + pc
BM, spleen, stomach  SM + pc + T-lb
BM, lung, stomach    SM + T-lb + mysarc
LN, spleen, thymus, gut  SM + T-lb
LN, liver, lung, stomach   SM + T-lb
spleen, liver, lung SM + T-lb
BM, LN, spleen, liver, kidney, thymus    SM + T-lb
spleen, liver, stomach   SM + pc + T-lb
Total  27/51
Results are derived from a complete necropsy and histopathological as well as immunohistochemical analysis of tissue sections 
in IL-9 transgenic mice transfected with NPM-ALK retrovirally-transformed bone marrow cells. Only mice in which malignant 
mast cell lesions had developed are shown. BM, bone marrow; LN, lymph nodes; SM, systemic mastocytosis; T-lb, T lympho-
blastic lymphoma; pc, plasmocytoma; pbl, plasmoblastic lymphoma; mysarc, myelosarcoma, mastsrc, mast cell sarcoma.111      Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
Morphology and histochemical characteristics of mast 
cells in IL-9 transgenic NPM-ALK+ mice
The morphology of MC varied from animal to animal 
and also from lesion to lesion, depending on the type of 
disease. In fact, MC often appeared to be rather mature and 
well granulated cells in MC hyperplasia and in animals 
exhibiting mastocytosis with small clusters and aggregates 
of MC (Figures 3 and 4). However, in animals develop-
ing aggressive MC disease, the morphology of neoplastic 
MC appeared to be immature, often with a hypogranulated 
cytoplasm and sometimes with bi- or polylobed nuclei. In 
all IL-9 transgenic NPM-ALK+ mice examined, neoplastic 
MC were found to stain positive for Giemsa and toluidine 
blue as well as Berberine sulfate (not shown), independent 
of the type of disease and organ/tissue site examined. We 
also found that neoplastic MC clearly stained positive for 
Naphthol AS-D chloroacetate esterase (CAE) (Figure 2C). 
Together, as assessed by morphology and cytochemistry, 
MC in most IL-9 transgenic NPM-ALK+ mice were found 
to resemble mature tissue MC. In mice with progressive 
MC  lesions,  however,  MC  were  found  to  be  immature 
hypogranulated cells, which is consistent with observations 
in human SM [7, 8].
Immunohistochemical properties of mast cells in IL-9/
NPM-ALK+ mice
In  a  first  step,  we  confirmed  that  neoplastic  MC  in 
IL-9 transgenic NPM-ALK-induced mastocytosis indeed 
expressed the NPM-ALK protein. For this purpose, ALK-1 
expression was examined by immunohistochemistry using 
the ARK-kit,  a  technique  in  which  the  mouse  antibody 
(ALK1) becomes saturated with biotinylated anti-mouse-
Fab fragment to reduce anti-mouse Ig-reactions and thus 
false-positive  reactions  through  Fc-binding  [61].  Using 
this technique, we were able to show that neoplastic MC 
in all affected tissues in all NPM-ALK+ mice invariably 
expressed the ALK protein (Table 4). Lymphoma cells also 
expressed the ALK protein in all NPM-ALK mice analyzed 
(Table 4), whereas the unaffected tissues in these animals 
were found to be ALK-negative. MC in MC hyperplasia in 
IL-9 transgenic mice (NPM-ALK-negative) did not stain 
positive with the ALK-antibody (not shown). In a second 
step, we examined the antigen profile of neoplastic MC 
in IL-9 transgenic NPM-ALK+ mice. As expected, these 
MC stained positive for CD45, CD117 (KIT), MC trypt-
ase (Figure 3C), and MC chymase (Table 4). An interesting 
aspect was that these MC also expressed CD25 (Figure 3D, 
Table 4), a marker that is typically expressed in neoplastic 
MC in human SM. Neoplastic MC did not express (other) 
T cell- or B cell antigens (CD3, CD4, CD5, CD8, CD19) 
(Table 4). We were also unable to detect CD23, CD38, or 
the progenitor antigen CD34 in neoplastic MC of these 
mice (Table 4). Vice versa, neoplastic cells in T cell- or B 
cell-lymphomas did not express MC-related antigens (KIT, 
tryptase, chymase) in any of the animals examined. A sum-
mary of staining results obtained in neoplastic cells in IL-9/
NPM-ALK+ mice is shown in Table 4.
Separation of lymphomas from mast cell tumors by 
transfer experiments
To study the (common) origin of lymphoma stem cells 
Table 4. Expression of lymphohematopoietic differentiation antigens in neoplastic cells in IL-9/NPM-ALK+ mice
Expression of leukocyte differentiation antigens in neoplastic cells was determined by immunohistochemistry and/or flow 
cytometry. With both techniques, identical results were obtained. LCA, leukocyte common antigen; ALK, anaplastic lym-
phoma kinase. +, expressed in all cells; +/-, expressed in a subpopulation or weak expression; -, not expressed.
Antigen/CD  Reactivity of cells with antibodies in
Lymphomas   Mastocytosis 
mast cell tumor
Myelosarcoma 
 T-type  pc/pb
TCR/CD3  +/- - - -
T4/CD4  +/- - - -
CD5 + - - -
T8/CD8  +/- - - -
CD19 -  +/- - -
FceRII/CD23 -  +/- - -
IL-2Rß/CD25  +/- - + -
CD34 - - - -
CD38 - + - -
LCA/CD45  +  +/- +  +/-
KIT/CD117 - - + -
Tryptase  - - + -
Chymase - - + -
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and mast cells in individual animals, transfer experiments 
were performed using isolated cells derived from lymphoma 
lesions  of  IL-9/NPM-ALK+  mice.  After  intraperitoneal 
injection  of  tumor  cells,  recipient  mice  (control  back-
ground = IL-9-negative or IL-9 transgenic mice) developed 
tumours within 4–10 weeks. The resulting neoplasms were 
invariably classified as lymphomas by histology and immu-
nophenotyping, with tumor-subtypes resembling the same 
histology as that of the injected tumors. However, no MC 
tumors developed in any of the secondary recipient mice 
examined. These data suggest that NPM-ALK transforms 
two distinct types of neoplastic stem cells in mice, i.e. a 
lymphoma stem cell and a MC stem cell, and that these 
two populations of cells grow independent from each other. 
Unfortunately, we were unable to perform experiments to 
generate a mastocytosis-like disease in secondary recipi-
ent mice, because it was not possible to predict whether 
the explanted organ would contain sufficient numbers of 
neoplastic MC (mastocytosis was rarely associated with 
tumor formation). In addition, lymphomas (either T-lym-
phoblastic or B-plasmocytic/blastic) were highly aggres-
sive and thus had a growth advantage over slowly growing 
MC lesions.
Detection of IL-9 mRNA and IL-9 receptors in IL-9 
transgenic NPM-ALK+ mice
Based on our mouse model, IL-9 is considered to play a 
potential role in the development of MC hyperplasia/mas-
tocytosis. Therefore, we were interested to learn whether 
mouse tissue samples would express IL-9 or IL-9 recep-
tor  mRNA. As  expected,  neoplastic  cells  in  the  tumors 
obtained from IL-9 transgenic mice expressed IL-9 mRNA 
(Figure 1). In addition, we were able to detect IL-9 receptor 
mRNA in these cells, although the transcript levels were 
rather low (Figure 1).
Detection of IL-9 mRNA and IL-9 receptors in the 
human mast cell leukemias cell line HMC-1
HMC-1  cells  were  found  to  exhibit  low  levels  of 
IL-9 mRNA and low but detectable levels of IL-9 recep-
tor mRNA as unstimulated cells. When exposed to LPS, 
HMC-1 cells were found to display higher levels of IL-9 
receptor  mRNA  (Figure  5A).  Surprisingly,  IL-9  mRNA 
levels even decreased after LPS treatment of HMC-1 cells 
(Figure 5A). We next explored whether HMC-1 cells also 
express the IL-9 receptor on their cell surface. As assessed 
by flow cytometry, we were indeed able to show that both 
HMC-1 subclones examined, i.e. HMC-1.1 (lacking KIT 
D816V)  and  HMC-1.2  cells  (expressing  KIT  D816V) 
express  the  IL-9  receptor  on  their  surface  (Figure  5B). 
Finally, we asked whether IL-9 would promote the growth 
of HMC-1 cells in vitro. As visible in Figure 5C, IL-9 was 
found to promote the growth of HMC-1.1 cells and HMC-
1.2 cells in a dose-dependenmt manner. These data suggest 
that neoplastic human MC, i.e. HMC-1 cells, express func-
tional receptors for IL-9.
Examination of primary neoplastic human MC for 
expression of IL-9 and IL-9 receptors  
To demonstrate expression of IL-9 and IL-9 receptors in 
primary human neoplastic MC in SM, a cohort of patients 
with human SM were examined using routine bone marrow 
sections and immunohistochemistry. Immunohistochemi-
Table 5. Expression of lymphohematopoietic antigens in 
neoplastic MC in human SM
Marker/ Antigen  Expression of antigen detected in BM mast cells 
by IHC* in
ISM    SSM   ASM MCL
Tryptase + + + +
CD117/KIT  + + + +
CD25 + + + +
CD30  - +/- + +
NPM(n) +/- + + +
NPM(c)  - - +/- +/-
ALK - - - -
Abbreviations: MC, mast cells; SM, systemic mastocytosis; BM, 
bone marrow; IHC, immunohistochemistry; ISM, indolent SM; SSM, 
smouldering SM; ASM, aggressive SM; MCL, mast cell leukemia; 
NPM(n), nuclear nucleophosmin; NPM(c) cytoplasmic nucleophos-
min. *Expression of antigens in BM MC was determined on serial 
BM sections by IHC using tryptase as MC-specific marker.
Figure 2. Mastocytosis in the bone marrow in an 
NPM-ALK-positive IL-9 transgenic mouse
The generation of IL-9 transgenic mice, transplantation 
of NPM-ALK positive progenitor cells, tissue process-
ing, and staining techniques are described in the text.   
(A, B): Giemsa-stained dense mast cell infiltrate in the 
bone marrow of an NPM-ALK-positive IL-9 transgenic 
mouse  is  shown  (magnification, A,  630x;  B,  1000x). 
The  higher  magnification  (B)  shows  that  most  mast 
cells (arrows) were round cells with moderately or well 
granulated cytoplasm and a round nucleus indicating 
an indolent variant of mastocytosis. Correspondingly, 
these mast cells were found to stain positive for Naph-
thol AS-D chloroacetate esterase (CAE) (x630) (C).113      Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
Figure 4. Mast cell infiltrates in various extramedullary organs 
in NPM-ALK-positive IL-9 transgenic mice. Tissue sections of 
various organs obtained from NPM-ALK-positive IL-9 transgenic 
mice  were  stained  by  Giemsa.  As  visible,  mast  cell  infiltrates 
(arrows) were detected in the lungs (A) (overview: magnification 
x20; insert x100), the liver (B) (overview x20; insert x400), the gas-
trointestinal tract (C, showing the esophago-gastric junction, x20), 
and the pancreas (D) (pancreatic gland, x400). In most instances, 
mast cells were found to be rather mature and well granulated cells 
consistent with the diagnosis of an indolent variant of a systemic 
mast cell disease. Some of these cells, however, were found to be 
more immature with a prominent nucleus, nucleoli, and a hypo-
granulated cytoplasm.
cal analysis on serial sections revealed strong expression 
of IL-9 receptors in neoplastic (tryptase+) MC in all SM 
cases examined. A typical example is shown in Figure 6. 
MC  in  normal  healthy  individuals  also  expressed  IL-9 
receptors (data not shown). In addition, we were able to 
show that neoplastic MC express IL-9 (Figure 6D). How-
ever, whereas the IL-9 receptor was detected in MC in all 
cases examined, IL-9 was expressed (weakly) in only 3/7 
patients analyzed. IL-9 was also found to be expressed by 
Hodgkin- and Sternberg-Reed cells in cases of Hodgkin´s 
lymphomas, which were employed as a positive control for 
IL-9 staining (not shown). In a final step, we asked whether 
neoplastic MC in SM express ALK or other lymphoma-
related  antigens  in  serial  BM  sections.  In  these  experi-
ments, we were able to show that tryptase+ MC co-express 
CD25 as well as nuclear NPM but did not express ALK, 
independent of the variant of SM (Table 5). An interest-
ing observation was that MC in aggressive SM expressed 
substantial amounts of NPM, sometimes even in their cyto-
plasm, whereas in ISM, NPM was only expressed weakly 
in MC, and was only detectable in the nuclei of neoplastic 
MC (Table 5). Confirming our previous observations [68, 
69], CD30 was found to be expressed in MC in ASM and 
MCL, whereas in ISM, most MC usually stained negative 
for CD30 (Table 5).
Figure 3. Mastocytosis infiltrates in the spleen in NPM-ALK-
positive IL-9 transgenic mice. The generation of IL-9 transgenic 
mice, transplantation of NPM-ALK positive progenitor cells, tissue 
processing, and staining techniques are described in the text. (A) 
shows a Giemsa-stained section of the spleen in an IL-9 trans-
genic, NPM-ALK-positive mouse (magnification, 100x, insert 400x). 
The splenic tissue is markedly infiltrated by mast cells (arrows) with 
subtotal replacement of the pre-existing red pulp. The white pulp is 
still preserved. Most mast cells were found to be round cells and 
to contain numerous metachromatic granules in their cytoplasm. 
These mast cells were also found to stain positive (red color) for 
Naphthol AS-D chloroacetate esterase (CAE) (100x) (B) and to co-
express tryptase (C) (x200) and CD25 (x200) (D) as assessed by 
immunohistochemistry (ABC method). For details of staining proto-
cols see text in Materials and Methods.114               Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
DISCUSSION
Several lines of evidence support the 'multi-hit' con-
cept of cancer development [70-72]. This concept is well 
established for various types of lymphohematopoietic neo-
plasms in man and mice [71, 72]. However, although many 
different  factors  and  genes  have  been  implicated  in  the 
regulation of growth of normal MC, little is known about 
oncogenic ‘hits’ that can act in concert to transform MC 
progenitors and thus lead to the clinical picture of overt 
mastocytosis. In the current study, we show that IL-9 and 
NPM-ALK each promote the production of MC in vivo, 
and that both act in concert to induce a mastocytosis-like 
disease in mice. In fact, IL-9 transgenic mice transplanted 
with NPM-ALK-transfected BM cells developed not only 
ALK+ lymphomas, but also various types of benign and 
malignant MC lesions. Based on their morphology, histol-
ogy, phenotypic properties, and on transfer experiments, 
MC  neoplasms  and ALK+  lymphomas  could  clearly  be 
distinguished in these mice.
A number of different cytokines including SCF, IL-3, 
IL-4, IL-9, and IL-13 have been described to act as MC 
differentiation- and growth factors in mice [21-28]. Corre-
spondingly, we were able to detect MC hyperplasia in most 
of  our  IL-9  transgenic  mice,  thereby  confirming  earlier 
observations [30]. However, these IL-9-triggered accumu-
lations of MC did by far not reach criteria for a primary MC 
disease (MC neoplasm=mastocytosis) in any of the animals 
examined.
The  observation  that  NPM-ALK  promotes  the  pro-
duction of MC, with resulting MC hyperplasia in various 
mouse tissues, was an unexpected result. In fact, NPM-
ALK has been described as a lymphoma-specific defect 
[51-53], but has not been implicated in the development 
of MC hyperplasia or an MC neoplasm so far. In addition, 
normal tissues and cells including myeloid progenitors in 
the BM, usually do not express ALK [54-56]. The unex-
pected effect of NPM-ALK on MC progenitors may have 
several explanations. First, this oncogene may target a very 
immature stem cell capable of giving rise to lymphoid and 
myelomastocytic  progenitors.  This  hypothesis  would  be 
supported by the concordant development of lymphomas 
Figure 5 . Expression of IL-9 and IL-9 receptors in HMC-1 cells
A: Expression of IL-9 mRNA, IL-9R1 mRNA, and IL-9R2 mRNA 
in HMC-1.2 cells after stimulation with lipopolysaccharide (LPS). 
HMC-1 cells were incubated with LPS (0.1 µg/ml) for various time 
periods (4-24 hours = h) as indicated. Thereafter, cells were ana-
lyzed  for  expression  of  IL-9  mRNA,  IL-9R1  mRNA,  and  IL-9R2 
mRNA by qPCR using primers depicted in Table 2. In the absence 
of LPS, baseline transcript levels did not change at any time point 
compared to time point “0” (not shown). B: Expression of surface 
IL-9 receptor on HMC-1.1 cells (left panel) and HMC-1.2 cells (right 
panel) as determined by flow cytometry. Cells were labelled with an 
anti-IL-9 receptor antibody (grey histogram) or an isotype-matched 
control antibody (stippeled histogram) by indirect immunofluores-
ence staining. C: Effects of IL-9 on growth of HMC-1.1 cells (left 
panel) and HMC-1.2 cells (right panel). HMC-1 cells were incu-
bated in control medium (Co) or various concentrations of IL-9 (as 
indicated) for 72 hours at 37°C. Thereafter, 3H-thymidine uptake 
was  measured.  Results  represent  thymidine  uptake  as  percent 
of control and show the mean±S.D. of three independent experi-
ments. Asterisk (*) indicates p<0.05 compared to control (Co). 
Figure 6. Expression of IL-9 and IL-9 receptor in primary human 
neoplastic mast cells (MC). Bone marrow sections obtained from 
a patient with systemic mastocytosis were stained with Giemsa (A) 
(magnification, x630), an antibody against tryptase (B) (x400), an 
antibody against the IL-9 receptor (C) (x1,000), and an antibody 
against IL-9 (D) (x1,000). The staining protocols are provided in the 
text. As visible, neoplastic MC were found to be immunoreactive for 
both IL-9 and the IL-9 receptor.115             Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
and MC neoplasms in mice, and by the occurrence of very 
immature  hematopoietic  (sometimes  myelosarcoma-like) 
neoplasms in some of these animals. It is noteworthy in this 
regard that NPM-ALK is a tyrosine kinase [53-55] and that 
several other tyrosine kinases can regulate growth of MC 
in mice [49, 50]. It is also noteworthy that NPM-ALK and 
KIT (as well as other tyrosine kinase receptors) may utilize 
similar downstream signaling pathways regulating growth 
and survival of neoplastic cells [53-55]. Another explana-
tion for the MC-promoting effect of NPM-ALK would be 
that malignant cells in the NPM-ALK-induced lymphomas 
produced cytokines that induced MC growth, such as IL-3 
or IL-4. In this regard it is noteworthy that the NPM-ALK-
induced lymphomas were often found to be of T cell origin, 
and that T cells usually produce and release huge amounts 
of such MC-targeting cytokines [21-23]. A third explana-
tion for the MC-promoting effect of NPM-ALK may be a 
specific effect of the NPM-component of the oncoprotein. 
Notably, it has been described that NPM is mutated and 
may play a pathogenetic role in other myeloid neoplasms, 
such as acute myeloid leukemia [73]. Furthermore, we were 
able to show in this study, that neoplastic MC in human 
SM express NPM, and that NPM-expression may correlate 
with the variant of SM. However, human neoplastic MC in 
SM did not express ALK, and similar to IL-9, NPM-ALK 
alone led to MC hyperplasia only, but did not lead to the 
clinical picture of overt mastocytosis.
The  observation  that  transplantation  of  NPM-ALK-
transfected progenitors into IL-9 transgenic mice results in a 
neoplastic disease resembling mastocytosis, is a remarkable 
phenomenon, and best explained by the ‘multi-hit’ theory 
of  cancer  development  [70-72]. Therefore,  although  the 
disease is clearly an artifical system, it may be useful and 
informative as an experimental model to study the develp-
ment of MC tumors. First, different types of MC tumors 
were found in these mice, including indolent forms and 
more aggressive disease variants, similar to the situation in 
human SM. Second, neoplastic MC in mouse tissues exhib-
ited morphological properties and phenotypic properties of 
neoplastic human MC [74]. Third, like in humans, mastocy-
tosis was often accompanied by an associated hematologic 
non-MC-lineage disease/neoplasm (AHNMD) as has been 
reported for human SM [7, 8]. These associated tumors, 
however, were mostly of lymphoid origin as opposed to 
human mastocytosis (SM-AHNMD where mostly myeloid 
neoplasms are found), which is best explained by the lym-
phoma-specific  trigger  (NPM-ALK)  used  to  induce  the 
MC disease in mice. In this regard, it is also noteworthy 
that neoplastic MC in human mastocytosis did not express 
ALK. On the other hand several of the IL-9/NPM-ALK+ 
mice developed plasmocytomas, a lymphoid neoplasm that 
is a relatively frequent AHNMD in human SM. Moreover, 
sometimes, Non Hodgkin´s lympohomas may be detect-
able in SM, and in these patients, lymphoma cells may 
express IL-9 receptors (H.H. and P.V., unpublished obser-
vation). Finally, neoplastic MC but not normal MC express 
several lymphoid marker antigens, such as CD2 and CD25 
as well as CD30 [68, 69, 75]. With regard to CD25 and 
CD30, these data were confirmed in the present study. A 
remarkable aspect is that CD30 is primarily detectable in 
advanced SM [69, 75], and that this antigen (Ki-1) is other-
wise also expressed in NPM/ALK+ lymphomas. Whether 
expression of CD30 is associated with overexpression of 
NPM in MC in advanced SM remains unknown. Alterna-
tively, abnormal expression of both antigens is regulated by 
the same mechanisms in neplastic MC. 
It is well established that murine MC express receptors 
for IL-9 and are responsive to this cytokine [27]. There-
fore,  we  asked  whether  NPM/ALK/IL-9-dependent  MC 
and  neoplastic  human  MC  (HMC-1  cells)  display  IL-9 
receptors. In these experiments we found that HMC-1 cells 
express detectable IL-9 receptor transcripts, and LPS was 
found to augment IL-9 receptor expression. In addition, we 
were able to show that HMC-1 cells display surface IL-9 
receptors by flow cytometry. Finally, we were able to show 
that primary bone marrow MC in patients with SM react 
with an antibody against the IL-9 receptor, and as men-
tioned above, the human MC leukemia cell line HMC-1 
also expressed the IL-9 receptor. Supporting these observa-
tions, we also found that IL-9 promotes the growth HMC-1 
cells in vitro. All these observations suggest that IL-9 might 
be an important cytokine contributing to the pathogenesis 
of SM, and that IL-9 may act as an autocrine or paracrine 
growth regulator. Notably, we found that HMC-1 cells and 
primary MC not only exhibit IL-9 receptors but also IL-9. 
In addition, IL-9 may be provided by surrounding cells in 
the tissues (e.g. by eosinophils or by TH2-cells), thereby 
promoting MC development in MC hyperplasia and SM. 
All in all, IL-9 and IL-9 receptors may indeed play a hith-
erto unrecognized role in the pathogenesis of SM, an obser-
vation that is in line with the notion that IL-9 is a growth 
regulator for normal MC [27].
The  MC-transforming  potential  of  the  NPM-ALK 
kinase  is  of  particular  interest.  MC  usually  grow  under 
the influence of SCF, the natural ligand of the KIT tyro-
sine kinase receptor [9-13]. However, other tyrosine kinase 
receptors are also able to trigger MC growth or may even 
substitute for KIT in KIT-deficient animals. Likewise, it has 
been described that ErbB can substitute for KIT as kinase 
to promote MC development in Kit-deficient mice [50]. 
In addition, ErbB expression may even lead to the devel-
opment of an MC neoplasm in mice [49]. Together with 
our data, these observations suggest that various tyrosine 
kinases (not only KIT) can trigger MC growth and survival, 
and can facilitate the development of MC tumors in mice. 
To which extent tyrosine kinases other than KIT play a role 
in naturally occurring (spontaneous) MC tumors in mice, 
remains at present unknown. 
The morphology and phenotpye of neoplastic MC in 
IL-9/NPM-ALK+  mice  was  of  interest  since  many  fea-116               Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
tures were found to resemble neoplastic MC in humans 
[74]. Likewise, MC were found to be either immature or 
mature cells, depending on  the  type of  the MC  disease 
and  aggressiveness  of  the  neoplasm,  similar  to  human 
SM  [74].  In  addition,  neoplastic  MC  were  occasionally 
found to be spindle-shaped MC similar to human neoplas-
tic MC [1-8, 74]. A remarkable finding was that neoplas-
tic  MC  displayed  CD25,  a  mastocytosis-related  marker 
that is selectively expressed on neoplastic MC, but not in 
normal tissue MC in humans [75, 76]. In addition, neo-
plastic murine MC were found to express KIT and tryptase 
as well as CAE corresponding to human (neoplastic) MC 
[77, 78]. In summary, several different morphologic and 
phenotypic  properties  of  MC  in  IL-9/NPM-ALK+  mice 
are highly reminicent of mastocytosis. On the other hand 
several questions concerning the impact/role of IL-9 and 
NPM or ALK in human SM, a disease that is considered 
to develop on the basis of a mutated KIT receptor (mostly 
KIT D816V), remain open. Likewise, it remains unknown 
whether KIT D816V or the murine equivalent KIT D814V 
would cooperate with IL-9 or NPM (or ALK) in inducing 
SM or triggering the progression of SM. In this regard it is 
noteworthy that neoplastic SM in advanced (human) SM 
were found to display substantial amounts of NPM, and 
sometimes even cytoplasmic NPM was detectable in these 
MC. Again, however, the possible cooperation of NPM and 
KIT or other factors (cytokines like IL-9) in the evolution of 
SM remains at present unknown. Here, novel robust mouse 
models including mice transgenic for murine or human KIT 
[79, 80], when combined with IL-9+ or NPM+ animals, 
should provide answers to these questions in future studies.
An interesting aspect in the current study was the simul-
taneous development of MC neoplasms and lymphomas 
in  individual  animals.  Both  neoplasms  apparently  were 
derived  from  immature  lymphohematopoietic  progeni-
tor (stem) cells and both were found to express ALK. In 
this regard it is noteworthy that MC in human SM are also 
considered to derive from immature (multipotent) hemato-
poietic progenitors [7, 8, 81]. It was therefore of particular 
importance to delineate both diseases by several different 
approaches. In a first step, we were able to show that both 
neoplasms expressed different phenotypes. In fact, neoplas-
tic MC did not express any of the T cell- or B cell-restricted 
antigens analyzed (except ALK), and the T cell- and B 
cell-lymphomas did not express MC antigens such as KIT, 
tryptase, or chymase. In a second step, we asked whether 
tumor-specific lymphoma stem cells in established ALK+ 
lymphomas can give rise to MC neoplasms in secondary 
recipients. However, although secondary recipients were 
found to develop ALK+ lymphomas in most cases, no MC 
neoplasms could be detected in any of these animals inde-
pendent of the presence or absence of an IL-9-background. 
These data support the conclusion that NPM-ALK-trans-
formed cells can be separated into two different categories, 
namely  MC-committed  (MC-neoplasm-committed)  pro-
genitors and lymphoma-committed (B cell- or T cell-com-
mitted) progenitors. In addition, some of these progenitors 
may be extremely immature without differentiation-capac-
ity – which then would result in the formation of extremely 
immature  (undifferentiated)  myelosarcoma-like  tumors 
that were also found to develop in some of the mice in this 
study.
In summary, our data show that IL-9 and NPM-ALK 
cooperate in producing a mastocytosis-like disease in mice 
that resembles a primary MC disease in several different 
aspects, and may thus be a useful model for studying the 
development and pathogensis of mastocytosis.
CONFLICT OF INTEREST
The authors declared no potential conflicts of interest 
with respect to this article.
ACKNOWLEDGEMENTS
We would like to thank Sabine Didlaukat and Christian 
Baumgartner for excellent technical assistance. This study 
was supported by the Deutsche Krebshilfe, grant #106683, 
Fonds zur Förderung der Wissenschaftlichen Forschung in 
Österreich (FWF), grant #P21173-B13, and Austrian Fed-
eral Ministry for Science and Research (GENAU-C.h.i.l.d. 
grant #GZ 200.136/1-VI/1/2005). 
REFERENCES 
1. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: 
a review. Histopathology 1979; 3:349-365.
2.  Metcalfe  DD.  Classification  and  diagnosis  of  mastocytosis: 
current status. J Invest Dermatol 1991; 96:2S-4S.
3. Valent P. Biology, classification and treatment of human masto-
cytosis. Wien Klin Wochenschr 1996; 108:385-397.
4. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of 
systemic mastocytosis: state of the art. Br J Haematol 2003; 
122:695-717. 
5. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 
2004; 55:419-432.
6.  Tefferi  A,  Pardanani  A.  Clinical,  genetic,  and  therapeutic 
insights into systemic mast cell disease. Curr Opin Hematol 
2004; 11:58-64. 
7. Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and 
classification of mastocytosis: a consensus proposal. Confer-
ence Report of “Year 2000 Working Conference on Mastocy-
tosis”. Leuk Res 2001; 25:603-625.
8. Valent P, Horny H-P, Li CY, et al. Mastocytosis (Mast cell dis-
ease). World Health Organization (WHO) Classification of 
Tumours. Pathology & Genetics. Tumours of Haematopoietic 
and Lymphoid Tissues. eds: Jaffe ES, Harris NL, Stein H, 
Vardiman JW. IARC Press, Lyon, France. 2001; pp 291-302.117      Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
9. Valent P, Spanblöchl E, Sperr WR, et al. Induction of differen-
tiation of human mast cells from bone marrow and peripheral 
blood mononuclear cells by recombinant human stem cell 
factor/kit-ligand in long-term culture. Blood 1992; 80:2237-
2245.
10. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the 
missing link? Immunol Today 1994; 15:111-114. 
11. Galli SJ, Iemura A, Garlick DS, Gamba-Vitalo C, Zsebo KM, 
Andrews  RG.  Reversible  expansion  of  primate  mast  cell 
populations in vivo by stem cell factor. J Clin Invest 1993; 
91:148-152. 
12. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, 
Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli 
SJ. Recombinant human stem cell factor (kit ligand) promotes 
human mast cell and melanocyte hyperplasia and functional 
activation in vivo. J Exp Med 1996; 183:2681-2686.
13. Jordan JH, Schernthaner GH, Fritsche-Polanz R, Sperr WR, 
Födinger M, Chott A, Geissler K, Lechner K, Horny HP, 
Valent P. Stem cell factor-induced bone marrow mast cell 
hyperplasia mimicking systemic mastocytosis (SM): histo-
pathologic and morphologic evaluation with special refer-
ence to recently established SM-criteria. Leuk Lymphoma 
2002; 43:575-582. 
14. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannen-
baum S, Suzuki Y, Metcalfe DD. Identification of a point 
mutation in the catalytic domain of the protooncogene c-kit 
in peripheral blood mononuclear cells of patients who have 
mastocytosis with an associated hematologic disorder. Proc 
Natl Acad Sci (USA) 1995; 92:10560-10564.
15. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, 
Duffy T, Jacobs P, Tang LH, Modlin I. Somatic c-kit acti-
vating mutation in urticaria pigmentosa and aggressive mas-
tocytosis: establishment of clonality in a human mast cell 
neoplasm. Nat Genet 1996; 12:312-314.
16. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu 
SZ, Heitjan D, Ma Y. Activating and dominant inactivating 
c-kit catalytic domain mutations in distinct forms of human 
mastocytosis.  Proc  Natl Acad  Sci  (USA)  1999;  96:1609-
1614.
17. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-
Plassmann G, Valent P, Födinger M. Mutation analysis of 
C-KIT in patients with myelodysplastic syndromes without 
mastocytosis and cases of systemic mastocytosis. Br J Hae-
matol 2001; 113:357-364. 
18. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. 
Kit and c-kit mutations in mastocytosis: a short overview 
with special reference to novel molecular and diagnostic con-
cepts. Int Arch Allergy Immunol 2002; 127:110-114.
19. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshi-
mizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama 
Y. Identification of mutations in the coding sequence of the 
proto-oncogene c-kit in a human mast cell leukemia cell line 
causing ligand-independent activation of the c-kit product. J 
Clin Invest 1993; 92:1736-1744.
20. Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, May-
erhofer M, Sperr WR, Arock M, Samorapoompichit P, Horny 
HP, Metcalfe DD. On the way to targeted therapy of mast cell 
neoplasms: identification of molecular targets in neoplastic 
mast cells and evaluation of arising treatment concepts. Eur J 
Clin Invest 2004; 34:41-52.
21. Ihle JN, Keller J, Oroszlan S Henderson LE, Copeland TD, 
Fitch  F,  Prystowsky  MB,  Goldwasser  E,  Schrader  JW, 
Palaszynski E, Dy M, Lebel B. Biologic properties of homo-
geneous interleukin 3. I. Demonstration of WEHI-3 growth 
factor activity, mast cell growth factor activity, p cell-stimu-
lating factor activity, colony-stimulating factor activity, and 
histamine-producing cell-stimulating factor activity. J Immu-
nol 1983; 131:282-287.
22. Razin E, Ihle JN, Seldin D, Mencia-Huerta JM, Katz HR, 
LeBlanc PA, Hein A, Caulfield JP, Austen KF, Stevens RL. 
Interleukin  3: A  differentiation  and  growth  factor  for  the 
mouse mast cell that contains chondroitin sulfate E proteo-
glycan. J Immunol 1984; 132:1479-1486. 
23. Hamaguchi Y, Kanakura Y, Fujita J, Takeda S, Nakano T, 
Tarui S, Honjo T, Kitamura Y. Interleukin 4 as an essential 
factor for in vitro clonal growth of murine connective tissue-
type mast cells. J Exp Med 1987; 165:268-273. 
24. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin 
FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock 
DC. Stem cell factor is encoded at the Sl locus of the mouse 
and is the ligand for the c-kit tyrosine kinase receptor. Cell 
1990; 63:213-224.
25. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, 
Cosman D, Anderson D, Lyman SD, Williams DE. Mast cell 
growth factor maps near the steel locus on mouse chromo-
some 10 and is deleted in a number of steel alleles. Cell 1990; 
63:175-183. 
26. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, 
March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS. 
Identification of a ligand for the c-kit proto-oncogene. Cell 
1990; 63:167-174. 
27. Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, 
Rude E, Dormer P, Van Snick J. Mast cell growth-enhancing 
activity (MEA) is structurally related and functionally iden-
tical to the novel mouse T cell growth factor P40/TCGFIII 
(interleukin 9). Eur J Immunol 1990; 20:1413-1416. 
28.  Thompson-Snipes  L,  Dhar  V,  Bond  MW,  Mosmann  TR, 
Moore KW, Rennick DM. Interleukin 10: a novel stimulatory 
factor for mast cells and their progenitors. J Exp Med 1991; 
173:507-510. 
29. Tsai M, Shih LS, Newlands GF, Takeishi T, Langley KE, 
Zsebo KM, Miller HR, Geissler EN, Galli SJ. The rat c-kit 
ligand, stem cell factor, induces the development of connec-
tive tissue-type and mucosal mast cells in vivo. Analysis by 
anatomical distribution, histochemistry, and protease pheno-
type. J Exp Med 1991; 174:125-131. 
30. Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, 
Grencis R, Renauld JC. Intraepithelial infiltration by mast 
cells  with  both  connective  tissue-type  and  mucosal-type 
characteristics in gut, trachea, and kidneys of IL-9 transgenic 
mice. J Immunol 1998; 160:3989-3996.
31. Kitamura Y, Go S. Decreased production of mast cells in S1/
S1d anemic mice. Blood 1979; 53:492-497. 
32. Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/
Wv mice and their increase by bone marrow transplantation. 
Blood 1978; 52:447-452.
33. Townsend JM, Fallon GP, Matthews JD, Smith P, Jolin EH, 118               Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
McKenzie  NA.  IL-9-deficient  mice  establish  fundamental 
roles  for  IL-9  in  pulmonary  mastocytosis  and  goblet  cell 
hyperplasia  but  not  T  cell  development.Immunity.  2000; 
13:573-583. 
34. Kitamura Y, Morii E, Jippo T, Ito A. Effect of MITF on mast 
cell differentiation. Mol Immunol 2002; 38:1173-1176. 
35.  Kitamura Y,  Morii  E,  Jippo T,  Ito A.  Regulation  of  mast 
cell phenotype by MITF. Int Arch Allergy Immunol 2002; 
127:106-109. 
36. Shelburne CP, McCoy ME, Piekorz R, Sexl VV, Gillespie SR, 
Bailey DP, Gharse A, Mirmonsef P, Mann MN, Kashyap M, 
Wright HV, Chong HJ, Bouton LA, Ramirez CD, Lantz CS, 
Ryan JJ. Stat5: an essential regulator of mast cell biology. 
Mol Immunol 2002; 38:1187-1191. 
37.  Shelburne  CP,  McCoy  ME,  Piekorz  R,  Sexl  V,  Roh  KH, 
Jacobs-Helber SM, Gillespie SR, Bailey DP, Mirmonsef P, 
Mann MN, Kashyap M, Wright HV, Chong HJ, Bouton LA, 
Barnstein B, Ramirez CD, Bunting KD, Sawyer S, Lantz CS, 
Ryan JJ. Stat5 expression is critical for mast cell development 
and survival. Blood 2003; 102:1290-1297. 
38. Ikeda K, Nakajima H, Suzuki K, Watanabe N, Kagami S, 
Iwamoto I. Stat5a is essential for the proliferation and sur-
vival of murine mast cells. Int Arch Allergy Immunol 2005; 
137:S1:45-50. 
39. Alfredsson  J,  Puthalakath  H,  Martin  H,  Strasser A,  Nils-
son G. Proapoptotic Bcl-2 family member Bim is involved 
in the control of mast cell survival and is induced together 
with Bcl-XL upon IgE-receptor activation. Cell Death Differ. 
2005; 12:136-144. 
40. Möller C, Alfredsson J, Engstrom M, Wootz H, Xiang Z, Lenn-
artsson J, Jönsson JI, Nilsson G. Stem cell factor promotes 
mast cell survival via inactivation of FOXO3a-mediated tran-
scriptional induction and MEK-regulated phosphorylation of 
the proapoptotic protein Bim. Blood 2005; 106:1330-1336.
41. Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, 
Matsuzawa Y, Kitamura Y, Kanakura Y. Ligand-independent 
activation of c-kit receptor tyrosine kinase in a murine masto-
cytoma cell line P-815 generated by a point mutation. Blood 
1994; 83:2619-2626. 
42. Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, 
Ishikawa J, Okabe M, Suzuki M, Yamamura K, Matsuzawa 
Y,  Kitamura Y,  Kanakura Y.  Neoplastic  transformation  of 
normal hematopoietic cells by constitutively activating muta-
tions of c-kit receptor tyrosine kinase. Blood 1996; 88:995-
1004. 
43. Piao X, Bernstein A. A point mutation in the catalytic domain 
of c-kit induces growth factor independence, tumorigenicity, 
and differentiation of mast cells. Blood 1996; 87:3117-3123.
44. Kunisada T, Lu SZ, Yoshida H, Nishikawa S, Nishikawa S, 
Mizoguchi M, Hayashi S, Tyrrell L, Williams DA, Wang X, 
Longley BJ. Murine cutaneous mastocytosis and epidermal 
melanocytosis induced by keratinocyte expression of trans-
genic stem cell factor. J Exp Med 1998; 187:1565-1573. 
45. Mizuki M, Sugahara H, Shibayama H, Kitamura Y, Kanakura 
Y.  Necessity  of  tyrosine  719  and  phosphatidylinositol 
3'-kinase-mediated signal pathway in constitutive activation 
and oncogenic potential of c-kit receptor tyrosine kinase with 
the Asp814Val mutation. Blood 2003; 101:1094-1102. 
46. Nair AP, Hirsch HH, Moroni C. Mast cells sensitive to v-H-ras 
transformation are hyperinducible for interleukin 3 expres-
sion and have lost tumor-suppressor activity. Oncogene 1992; 
7:1963-1972.
47. Majeed SK. Mast cell tumours in CD-1 mice. Arzneimittel-
forschung. 1991; 41:175-178. 
48. Tanaka T, Rivenson A. Mastocytoma induced by cigarette 
smoke particulates: "cigarette tar". Arch Dermatol Res 1986; 
279:130-135. 
49. von Ruden T, Kandels S, Radaszkiewicz T, Ullrich A, Wagner 
EF. Development of a lethal mast cell disease in mice recon-
stituted with bone marrow cells expressing the v-erbB onco-
gene. Blood 1992; 79:3145-3158. 
50. von Ruden T, Stingl L, Ullrich A, Wagner EF. Rescue of 
W-associated mast cell defects in W/Wv bone marrow cells 
by  ectopic  expression  of  normal  and  mutant  epidermal 
growth factor receptors. Blood 1993; 82:1463-1470. 
51. Benharroch D, Meguerian-Bedoyan Z, Lamant L, , Amin C, 
Brugières L, Terrier-Lacombe MJ, Haralambieva E, Pulford 
K, Pileri S, Morris SW, Mason DY, Delsol G. ALK-positive 
lymphoma: a single disease with a broad spectrum of mor-
phology. Blood 1998; 91:2076-2084.
52.  Pulford  K,  Morris  SW,  Mason  DY. Anaplastic  lymphoma 
kinase proteins and malignancy. Curr Opin Hematol 2001; 
8:231-236. 
53. Pulford K, Morris SW, and Turturro F. Anaplastic lymphoma 
kinase proteins in growth control and cancer. J Cell Physiol 
2004; 199:330-358.
54. Duyster J, Bai RY, Morris SW. Translocations involving ana-
plastic lymphoma kinase (ALK). Oncogene 2001; 20:5623-
5637. 
55. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro 
DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to 
a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. 
Science 1994; 263:1281-1284.
56. Bullrich F, Morris SW, Hummel M, Pileri S, Stein H, Croce 
CM. Nucleophosmin (NPM) gene rearrangements in Ki-1-
positive lymphomas. Cancer Res 1994; 54:2873-2877.
57. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, 
Mason DY, Morris SW. Retrovirus-mediated gene transfer 
of NPM-ALK causes lymphoid malignancy in mice. Blood 
1997; 90:2901-2910.
58. Miething C, Grundler R, Fend F, Hoepfl J, Mugler C, von 
Schilling C, Morris SW, Peschel C, Duyster J. The oncogenic 
fusion protein nucleophosmin-anaplastic lymphoma kinase 
(NPM-ALK) induces two distinct malignant phenotypes in 
a murine retroviral transplantation model. Oncogene 2003; 
22:4642-4647.
59. Bittner C, Feller AC, Renauld JC, Lange K, Pietrzik R, Jen-
etzky C, Briese J, Gaiser T, Müller A, Wiedemann GJ, Van 
Snick J, Merz H. An animal model for anaplastic large cell 
lymphoma  in  the  immunocompetent  syngeneic  C57Bl/6 
mouse. Lab Invest 2000; 80:1523-1531.
60. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Sim-
mons WJ, Dhall G, Howes J, Piva R, Inghirami G. NPM-ALK 
transgenic  mice  spontaneously  develop  T-cell  lymphomas 
and plasma cell tumors. Blood 2003; 101:1919-1927.
61. Lange K, Uckert W, Blankenstein T, Nadrowitz R, Bittner C, 119      Oncotarget 2010; 1: 104-119 www.impactjournals.com/oncotarget/
Renauld JC, van Snick J, Feller AC, Merz H. Overexpression 
of NPM-ALK induces different types of malignant lympho-
mas in IL-9 transgenic mice. Oncogene 2003; 22:517-527.
62. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten 
G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT. 
FVB/N:  an  inbred  mouse  strain  preferable  for  transgenic 
analyses. Proc Natl Acad Sci (USA) 1991; 88:2065-2069. 
63. Renauld JC, van der Lugt N, Vink A, van Roon M, God-
fraind C, Warnier G, Merz H, Feller A, Berns A, Van Snick J. 
Thymic lymphomas in interleukin 9 transgenic mice. Onco-
gene 1994; 9:1327-1332.
64. Maes B, Vanhentenrijk V, Wlodarska I, Cools J, Peeters B, 
Marynen  P,  de  Wolf-Peeters  C.  The  NPM-ALK  and  the 
ATIC-ALK fusion genes can be detected in non-neoplastic 
cells. Am J Pathol 2001; 158:2185-2193.
65. Livak KJ, Schmittgen TD. Analysis of relative gene expres-
sion data using real-time quantitative PCR and the 2(-Delta 
Delta C(T)) Method. Methods 2001; 25:402-408.
66. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment 
of an immature mast cell line from a patient with mast cell 
leukemia. Leuk Res 1988; 12:345-355.
67. Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer 
M, Gleixner KV, Fritz R, Kerenyi M, Boudot C, Gouilleux F, 
Kornfeld JW, Sillaber C, Moriggl R, Valent P. Expression of 
activated STAT5 in neoplastic mast cells in systemic masto-
cytosis: subcellular distribution and role of the transforming 
oncoprotein KIT D816V. Am J Pathol 2009; 175:2416-2429.
68. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, Hessel H, Ber-
ezowska  S,  Müllauer  L,  Valent  P,  Horny  HP:  Aberrant 
expression of CD30 in neoplastic mast cells in high grade 
mastocytosis. manuscript submitted.
69. Valent P, Cerny-Reiterer S, Herrmann H, Mirkina I, George 
T, Sotlar K, Sperr WR, Horny HP: Phenotypic heterogeneity 
and target expression profiles of normal and neoplastic mast 
cells. Best Pract & Res Clin Haematol, in press. 2010.
70. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, 
Brooks MW, Weinberg RA. Creation of human tumour cells 
with defined genetic elements. Nature 1999; 400:464-468. 
71. Hahn WC, Weinberg RA. Modelling the molecular circuitry 
of cancer. Nat Rev Cancer 2002; 2:331-341. 
72. Hahn WC, Weinberg RA. Rules for making human tumor 
cells. N Engl J Med. 2002; 347:1593-1603. 
73. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqua-
lucci L, La Starza R, Diverio D, Colombo E, Santucci A, 
Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi 
P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, 
Pelicci  PG,  Martelli  MF.  Cytoplasmic  nucleophosmin  in 
acute  myelogenous  leukemia  with  a  normal  karyotype.  N 
Engl J Med 2005; 352:254-266. 
74. Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi 
M, Horny HP, Valent P. Morphologic properties of neoplastic 
mast cells: delineation of stages of maturation and implica-
tion for cytological grading of mastocytosis. Leuk Res 2001; 
25:529-536. 
75. Escribano L, Diaz-Agustin B, Bellas C, Navalón R, Nuñez 
R, Sperr WR, Schernthaner GH, Valent P, Orfao A. Utility 
of flow cytometric analysis of mast cells in the diagnosis and 
classification of adult mastocytosis. Leuk Res 2001; 25:563-
570.
76. Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger 
KJ,  Mayerhofer  M,  Printz  D,  Fritsch  G,  Valent  P.  CD25 
indicates  the  neoplastic  phenotype  of  mast  cells:  a  novel 
immunohistochemical marker for the diagnosis of systemic 
mastocytosis  (SM)  in  routinely  processed  bone  marrow 
biopsy specimens. Am J Surg Pathol 2004; 28:1319-1325.
 77. Horny H-P, Sillaber C, Menke D, Kaiserling E, Wehrmann 
M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P. 
Diagnostic value of immunostaining for tryptase in patients 
with mastocytosis. Am J Surg Pathol 1998; 22:1132-1140.
78. Horny H-P, Valent P. Diagnosis of mastocytosis: general histo-
pathological aspects, morphological criteria, and immunohis-
tochemical findings. Leuk Res 2001; 25:543-551.
79. Zappulla JP, Dubreuil P, Desbois S, Létard S, Hamouda NB, 
Daëron  M,  Delsol  G, Arock  M,  Liblau  RS.  Mastocytosis 
in mice expressing human Kit receptor with the activating 
Asp816Val mutation. J Exp Med 2005; 202:1635-1641.
80. Scholten J, Hartmann K, Gerbaulet A, Krieg T, Müller W, 
Testa  G,  Roers  A.  Mast  cell-specific  Cre/loxP-mediated 
recombination in vivo. Transgenic Res 2008; 17:307-315.
81. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evi-
dence for the involvement of a hematopoietic progenitor cell 
in systemic mastocytosis from single-cell analysis of muta-
tions in the c-kit gene. Blood 2002; 100:661-665.